Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin

Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody–drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. F...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinert, Jochim, Beitzen-Heineke, Antonia, Wethmar, Klaus, Stelljes, Matthias, Fiedler, Walter, Schwartz, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510963/
https://www.ncbi.nlm.nih.gov/pubmed/34331563
http://dx.doi.org/10.1007/s00277-021-04601-0
_version_ 1784582685964894208
author Reinert, Jochim
Beitzen-Heineke, Antonia
Wethmar, Klaus
Stelljes, Matthias
Fiedler, Walter
Schwartz, Stefan
author_facet Reinert, Jochim
Beitzen-Heineke, Antonia
Wethmar, Klaus
Stelljes, Matthias
Fiedler, Walter
Schwartz, Stefan
author_sort Reinert, Jochim
collection PubMed
description Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody–drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities.
format Online
Article
Text
id pubmed-8510963
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85109632021-10-27 Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin Reinert, Jochim Beitzen-Heineke, Antonia Wethmar, Klaus Stelljes, Matthias Fiedler, Walter Schwartz, Stefan Ann Hematol Original Article Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody–drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities. Springer Berlin Heidelberg 2021-07-31 2021 /pmc/articles/PMC8510963/ /pubmed/34331563 http://dx.doi.org/10.1007/s00277-021-04601-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Reinert, Jochim
Beitzen-Heineke, Antonia
Wethmar, Klaus
Stelljes, Matthias
Fiedler, Walter
Schwartz, Stefan
Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
title Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
title_full Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
title_fullStr Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
title_full_unstemmed Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
title_short Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
title_sort loss of cd22 expression and expansion of a cd22(dim) subpopulation in adults with relapsed/refractory b-lymphoblastic leukaemia after treatment with inotuzumab-ozogamicin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510963/
https://www.ncbi.nlm.nih.gov/pubmed/34331563
http://dx.doi.org/10.1007/s00277-021-04601-0
work_keys_str_mv AT reinertjochim lossofcd22expressionandexpansionofacd22dimsubpopulationinadultswithrelapsedrefractoryblymphoblasticleukaemiaaftertreatmentwithinotuzumabozogamicin
AT beitzenheinekeantonia lossofcd22expressionandexpansionofacd22dimsubpopulationinadultswithrelapsedrefractoryblymphoblasticleukaemiaaftertreatmentwithinotuzumabozogamicin
AT wethmarklaus lossofcd22expressionandexpansionofacd22dimsubpopulationinadultswithrelapsedrefractoryblymphoblasticleukaemiaaftertreatmentwithinotuzumabozogamicin
AT stelljesmatthias lossofcd22expressionandexpansionofacd22dimsubpopulationinadultswithrelapsedrefractoryblymphoblasticleukaemiaaftertreatmentwithinotuzumabozogamicin
AT fiedlerwalter lossofcd22expressionandexpansionofacd22dimsubpopulationinadultswithrelapsedrefractoryblymphoblasticleukaemiaaftertreatmentwithinotuzumabozogamicin
AT schwartzstefan lossofcd22expressionandexpansionofacd22dimsubpopulationinadultswithrelapsedrefractoryblymphoblasticleukaemiaaftertreatmentwithinotuzumabozogamicin

Ejemplares similares